MIRM Q4 2023 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+149.2% YoY

Gross Profit

$45M64.0% margin

Operating Income

-$33M-46.8% margin

Net Income

-$36M-51.3% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+45.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$22M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$647M

Total Liabilities

$398M

Stockholders' Equity

$249M

Cash & Equivalents

$286M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$28M	+149.2%
Gross Profit	$45M	$23M	+90.2%
Operating Income	-$33M	-$34M	+4.6%
Net Income	-$36M	-$36M	+2.1%

Revenue Segments

Product

$70M100%